The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL
Javier Pinilla-Ibarz, MD, PhD, from H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, provides us an overview of a Phase III trial (NCT02612311) evaluating the combination of the novel PI3K delta inhibitor, TGR-1202, with ublituximab in the treatment of chronic lymphocytic leukemia (CLL). He looks forward to observing how the combination will pan out in terms of whether it displays increased efficacy, which would be helpful in the development of new treatments for CLL. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
